Introduction and aim Infective endocarditis (IE) cases are on the rise in the United States. The incidence of IE in patients with inflammatory bowel disease (IBD) has not been reported. Utilizing a national level database, we sought to estimate the incidence of IE in IBD-related hospitalizations and to determine its outcomes.  Methods Discharge records from the National Inpatient Sample were analyzed, and the International Classification of Diseases, ninth revision, Clinical Modification codes (ICD-9-CM) was used to identify adult patients with IBD (Crohn's disease or ulcerative colitis) and IE between 2003 and 2014. Trends in the incidence of IE were recorded and multivariable regression was used to determine the impact of IE on IBD-hospitalizations. Results The incidence of IE in patients with IBD rose from 14.5 cases per 10,000 admissions in 2003 to 21.7 in 2014. After multivariable adjustment, both patient groups with CD (odds ratio [OR] 3.5, 95% confidence interval [CI] 3.0-4.1) and UC (OR 2.9, 95% CI 2.5-3.5) admitted with IE were found to be at greater risk for in-hospital mortality compared to non-IE admissions. Patients with IBD admitted with IE were found to have greater mean length of stay (13 days vs. six days, p<0.0001) and higher average hospital charges ($36,869.85 vs. $13,324.01, p <0.0001) compared to non-IE admissions.  Conclusions Infective endocarditis is a growing complication in patients with IBD and is associated with increased mortality and utilization of healthcare resources. Further studies addressing the association between IE and IBD are needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7061780PMC
http://dx.doi.org/10.7759/cureus.6919DOI Listing

Publication Analysis

Top Keywords

patients ibd
12
infective endocarditis
8
patients inflammatory
8
inflammatory bowel
8
bowel disease
8
incidence patients
8
admitted greater
8
patients
5
increasing rates
4
rates infective
4

Similar Publications

Background: The pharmacokinetics of biologic agents can differ between children and adults with inflammatory bowel disease (IBD), often necessitating modified paediatric dosing strategies.

Aims: To define the exposure-response relationship of vedolizumab in the paediatric IBD VedoKids cohort including the effect of baseline clearance on deep biochemical remission (normal C-reactive protein [CRP]/erythrocyte sedimentation rate [ESR] and steroid-free remission) at 30 weeks, and to use population pharmacokinetic models to find the best matches between adult and paediatric pharmacokinetic profiles.

Methods: We sought a pharmacokinetic model on 312 serum vedolizumab concentrations from 129 children, assisted by a published adult model as a Bayesian prior.

View Article and Find Full Text PDF

Crohn's disease (CD) and ulcerative colitis (UC) are chronic relapsing inflammatory bowel disorders (IBD), the pathogenesis of which is uncertain but includes genetic susceptibility factors, immune-mediated tissue injury and environmental influences, most of which appear to act via the gut microbiome. We hypothesized that host-microbe alterations could be used to prognostically stratify patients experiencing relapses up to four years after endoscopy. We therefore examined multiple omics data, including published and new datasets, generated from paired inflamed and non-inflamed mucosal biopsies from 142 patients with IBD (54 CD; 88 UC) and from 34 control (non-diseased) biopsies.

View Article and Find Full Text PDF

[Not Available].

Tunis Med

January 2025

Department of Rheumatology, Kassab Institute of Orthopaedics, Mannouba. Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia.

Aim: To develop good practice recommendations (GPR) for the therapeutic management of patients with spondyloarthritis (SpA), including psoriatic arthritis.

Methods: Following standardised procedures, a systematic review of the literature was carried out on non-pharmacological and non-biological pharmacological treatments for SpA. The review was based on questions defined by a working group of 15 rheumatologists.

View Article and Find Full Text PDF

Introduction: Ophthalmological manifestations (O-EIM) are one of the extraintestinal manifestations (EIM) of inflammatory bowel disease (IBD), although their frequency and potential relationship with disease activity and treatment remain underestimated.

Aim: The aim of this screening questionnaire was to assess the number of EIM, including O-EIM, among patients with IBD.

Material And Methods: 436 patients with IBD and 102 patients without IBD were included in this single-centre retrospective study.

View Article and Find Full Text PDF

Introduction: Inflammatory bowel disease patients are exposed to frequent procedures and hospital admissions as well as recurrent need for radiological examinations with a high risk of exposure to radiation and contrast.

Aim: Our objective was to evaluate the role of a combination of both intestinal ultrasound (IUS) and colour Doppler with different parameters for monitoring changes in inflammation over time and to reveal their potential role in the assessment of response to biologic therapy in inflammatory bowel disease (IBD) patients.

Material And Methods: Before the induction of biological therapy, IUS together with colour Doppler of the intestine was conducted.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!